Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer

IF 3.3 Q1 ONCOLOGY Lung Cancer: Targets and Therapy Pub Date : 2016-11-30 DOI:10.2147/LCTT.S116762
B. Legius, S. van den Broecke, I. Muylle, V. Ninane
{"title":"Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer","authors":"B. Legius, S. van den Broecke, I. Muylle, V. Ninane","doi":"10.2147/LCTT.S116762","DOIUrl":null,"url":null,"abstract":"Non-small cell lung cancer can exhibit driver oncogenes, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), that are possible targets for therapy. The prevalence of these rearranged driver oncogenes is influenced by race, smoking habits, and gender. Most data come from Caucasian and Asian populations. To our knowledge, there is no literature available about the prevalence of driver oncogenes in Sub-Saharan Africa, where the tobacco epidemic is still in the early stage. In this small case series, 6 patients of Sub-Saharan African ethnicity with stage IV lung adenocarcinoma are described. EGFR mutation was present in 3/6 patients and ALK rearrangement in 1/6 patients. This incidence seems high but interestingly, all patients were non-smokers or light smokers. In this series, the high prevalence of driver oncogene was probably related to low smoking habits and these initial data in Sub-Saharan Africans suggest high prevalence of driver mutations for this reason.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"5 1","pages":"149 - 152"},"PeriodicalIF":3.3000,"publicationDate":"2016-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S116762","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Non-small cell lung cancer can exhibit driver oncogenes, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), that are possible targets for therapy. The prevalence of these rearranged driver oncogenes is influenced by race, smoking habits, and gender. Most data come from Caucasian and Asian populations. To our knowledge, there is no literature available about the prevalence of driver oncogenes in Sub-Saharan Africa, where the tobacco epidemic is still in the early stage. In this small case series, 6 patients of Sub-Saharan African ethnicity with stage IV lung adenocarcinoma are described. EGFR mutation was present in 3/6 patients and ALK rearrangement in 1/6 patients. This incidence seems high but interestingly, all patients were non-smokers or light smokers. In this series, the high prevalence of driver oncogene was probably related to low smoking habits and these initial data in Sub-Saharan Africans suggest high prevalence of driver mutations for this reason.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
撒哈拉以南非洲非小细胞肺癌患者的驱动癌基因
非小细胞肺癌可以表现出驱动癌基因,包括表皮生长因子受体(EGFR)和间变性淋巴瘤激酶(ALK),它们可能是治疗的靶点。这些重新排列的驱动癌基因的流行受种族、吸烟习惯和性别的影响。大多数数据来自高加索人和亚洲人。据我们所知,在烟草流行仍处于早期阶段的撒哈拉以南非洲,尚无关于驱动癌基因流行的文献。在这个小病例系列中,描述了6例撒哈拉以南非洲种族的IV期肺腺癌患者。3/6的患者存在EGFR突变,1/6的患者存在ALK重排。这种发病率似乎很高,但有趣的是,所有患者都是不吸烟者或轻度吸烟者。在这个系列中,驱动癌基因的高流行率可能与低吸烟习惯有关,这些撒哈拉以南非洲地区的初步数据表明,驱动突变的高流行率正是出于这个原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.10
自引率
0.00%
发文量
10
审稿时长
16 weeks
期刊最新文献
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer. Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report. Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC - Insights From Genomics, Proteomics, and Metabolomics. Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker. A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1